Strongbridge Biopharma PLC Company Profile (NASDAQ:SBBP)

About Strongbridge Biopharma PLC (NASDAQ:SBBP)

Strongbridge Biopharma PLC logoStrongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SBBP
  • CUSIP: N/A
  • Web: www.strongbridgebio.com
Capitalization:
  • Market Cap: $244.84 million
  • Outstanding Shares: 35,335,000
Average Prices:
  • 50 Day Moving Avg: $6.59
  • 200 Day Moving Avg: $5.83
  • 52 Week Range: $2.00 - $8.85
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.84
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.53 million
  • Price / Sales: 142.03
  • Book Value: $0.28 per share
  • Price / Book: 21.96
Profitability:
  • EBITDA: ($39,430,000.00)
  • Return on Equity: -83.83%
  • Return on Assets: -34.77%
Debt:
  • Debt-to-Equity Ratio: 1.89%
  • Current Ratio: 4.63%
  • Quick Ratio: 4.46%
Misc:
  • Average Volume: 113,512 shs.
  • Beta: 2.71
  • Short Ratio: 10.35
 

Frequently Asked Questions for Strongbridge Biopharma PLC (NASDAQ:SBBP)

What is Strongbridge Biopharma PLC's stock symbol?

Strongbridge Biopharma PLC trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma PLC's earnings last quarter?

Strongbridge Biopharma PLC (NASDAQ:SBBP) posted its earnings results on Monday, August, 7th. The company reported ($0.34) EPS for the quarter, hitting analysts' consensus estimates of ($0.34). The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.84 million. View Strongbridge Biopharma PLC's Earnings History.

When will Strongbridge Biopharma PLC make its next earnings announcement?

Strongbridge Biopharma PLC is scheduled to release their next quarterly earnings announcement on Friday, December, 22nd 2017. View Earnings Estimates for Strongbridge Biopharma PLC.

Where is Strongbridge Biopharma PLC's stock going? Where will Strongbridge Biopharma PLC's stock price be in 2017?

3 brokers have issued 1-year target prices for Strongbridge Biopharma PLC's stock. Their forecasts range from $10.00 to $18.00. On average, they expect Strongbridge Biopharma PLC's stock price to reach $13.33 in the next twelve months. View Analyst Ratings for Strongbridge Biopharma PLC.

Who are some of Strongbridge Biopharma PLC's key competitors?

Who are Strongbridge Biopharma PLC's key executives?

Strongbridge Biopharma PLC's management team includes the folowing people:

  • John H. Johnson, Chairman of the Board
  • Matthew Pauls J.D., Chief Executive Officer, Director
  • A. Brian Davis, Chief Financial Officer
  • Stephen J. Long, Chief Legal Officer
  • Robert Lutz, Chief Business Officer
  • Ruth Thieroff-Ekerdt M.D., Chief Medical Officer
  • Richard S. Kollender, Director
  • Garheng Kong M.D. Ph.D., Director
  • Marten Steen, Director
  • Hilde H Steineger, Director

Who owns Strongbridge Biopharma PLC stock?

Strongbridge Biopharma PLC's stock is owned by many different of institutional and retail investors. Top institutional investors include ARMISTICE CAPITAL, LLC (5.10%). View Institutional Ownership Trends for Strongbridge Biopharma PLC.

How do I buy Strongbridge Biopharma PLC stock?

Shares of Strongbridge Biopharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Strongbridge Biopharma PLC's stock price today?

One share of Strongbridge Biopharma PLC stock can currently be purchased for approximately $6.15.


MarketBeat Community Rating for Strongbridge Biopharma PLC (NASDAQ SBBP)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Strongbridge Biopharma PLC (NASDAQ:SBBP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.33 (116.80% upside)
Consensus Price Target History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Price Target History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Analysts' Ratings History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Oppenheimer Holdings, Inc.Initiated CoverageOutperform$12.00HighView Rating Details
5/17/2017HC WainwrightReiterated RatingBuyLowView Rating Details
12/28/2016JMP SecuritiesReiterated RatingOutperform$10.00N/AView Rating Details
2/3/2016Roth CapitalInitiated CoverageBuy$12.00N/AView Rating Details
12/10/2015Janney Montgomery ScottInitiated CoverageBuy$19.00N/AView Rating Details
12/7/2015Stifel NicolausReiterated RatingBuyN/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Earnings by Quarter for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Earnings History by Quarter for Strongbridge Biopharma PLC (NASDAQ SBBP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/22/2017        
8/7/2017Q2 2017($0.34)($0.34)$0.84 million$1.53 millionViewListenView Earnings Details
5/16/20173/31/2017($0.49)($0.33)ViewN/AView Earnings Details
5/17/2016Q1($0.63)($0.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Current Year EPS Consensus Estimate: $-2.66 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS

Dividends

Dividend History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Latest Headlines for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Source:
Loading headlines, please wait.

Social

Chart

Strongbridge Biopharma PLC (SBBP) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.